6 Top Gainers In Healthcare Sector (LOGC, CDTX, QDEL…)

(RTTNews) - The following are some of today's top gainers in the healthcare sector.

1. LogicBio Therapeutics Inc. (LOGC)

LogicBio is a genome editing company focused on developing medicines for rare diseases.

Gained 29.46% to close Thursday's (Aug.29) trading at $9.58.

News: No news

Clinical Trials & Near-term Catalysts:

-- The Company expects to file an IND for LB-001 in the fourth quarter of 2019 and initiate a Phase 1/2 trial in methylmalonic academia, an inborn error of metabolism, in the first half of 2020. Preliminary data from this trial is expected in the second half of 2020.

2. Cidara Therapeutics Inc. (CDTX)

Cidara Therapeutics is a clinical-stage biotechnology company developing novel anti-infectives, including immunotherapies.

Gained 16.34% to close Thursday's trading at $1.78.

News: No news

Clinical Trials & Near-term Catalysts:

The Company's lead antifungal candidate is Rezafungin.

-- In July of this year, the Company announced positive topline results from its phase II trial of Rezafungin in the treatment of patients with candidemia and/or invasive candidiasis, dubbed STRIVE B. -- A global phase III clinical trial of Rezafungin for the first-line treatment of candidemia and/or invasive candidiasis, dubbed ReSTORE, is ongoing.

Cash position:

As of June 30, 2019, the Company had cash, cash equivalents and short-term investments of $44.6 million.

3. DiaMedica Therapeutics Inc. (DMAC)

DiaMedica Therapeutics is a clinical-stage biopharmaceutical company developing novel treatments for kidney diseases and neurological disorders.

Gained 16.13% to close Thursday's trading at $2.88.

News: No news

Clinical Trials & Near-term Catalysts:

-- Enrollment and patient follow-up in a phase Ib clinical trial of DM199 in patients with moderate or severe Chronic Kidney Disease caused by Type I or Type II diabetes mellitus has been completed. The interim results have already been reported and they were positive. The full results of the study are expected to be provided in a peer-reviewed publication and/or poster presentation.

-- A phase II, multiple cohort study of DM199 in IgA Nephropathy and Hypertensive African Americans with Chronic Kidney Disease is anticipated to start in the second half of 2019.

-- A phase II study of DM199 for the treatment of Acute Ischemic Stroke, dubbed REMEDY, is ongoing. This study is expected to be completed in the fourth quarter of 2019 or first quarter of 2020.

Cash position:

The Company had cash and cash equivalents of $3.0 million, marketable securities of $8.0 million, current liabilities of $947,000 and working capital of $11.3 million as of June 30, 2019.

4. Nuvectra Corporation (NVTR)

Nuvectra is a neurostimulation medical device company marketing CE marked and FDA approved Algovita Spinal Cord Stimulation (SCS) System for the treatment of chronic intractable pain of the trunk and/or limbs.

Gained 15.66% to close Thursday's trading at $2.29.

News: No news

Recent event:

On August 26, 2019, the Company announced it has decided to explore potential strategic alternatives, including a sale or merger, in order to best assure future innovation, product commercialization and growth and to enhance shareholder value.

Piper Jaffray is expected to be engaged as the Company's financial advisor.

5. Aeterna Zentaris Inc. (AEZS)

Aeterna Zentaris is a specialty biopharmaceutical company engaged in commercializing novel pharmaceutical therapies, principally through out-licensing arrangements.

Gained 15.94% to close Thursday's trading at $2.40.

News: No news

6. Quidel Corporation (QDEL)

Quidel is a provider of rapid diagnostic testing solutions, cellular-based virology assays, and molecular diagnostic systems.

Gained 12.81% to close Thursday's trading at $65.62.

News: No news

Recent event:

On August 8, 2019, the Company reported financial results for the second quarter ended June 30, 2019.

Net income for the second quarter was $1.3 million or $0.03 per share compared to a net loss of $3.1 million or $0.08 per share for the second quarter of 2018. On a non-GAAP basis, net income for the second quarter of 2019 was $15.4 million or $0.36 per diluted share, as compared to net income of $15.9 million, or $0.37 per diluted share, for the same period in 2018.

Total revenue for the second quarter of 2019 was $108.3 million, up from $103.2 million for the second quarter of 2018.